Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (161-170 of 436) with videos related to

Pageof 44
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2025
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class RearrangementsJulie Braish, Hagop Kantarjian, Nicholas J Short, et al.
Leukemia|April 9, 2021
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemiaFrancesco Paolo Tambaro, Harjeet Singh, Emily Jones, et al.
British Journal of Haematology|July 21, 2020
Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemiaShilpa Paul, Nadya Jammal, Neal Akhave, et al.
Blood Advances|September 23, 2021
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapyHussein A Abbas, Zoe Alaniz, Sean Mackay, et al.
Haematologica|July 13, 2019
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantationSamer A Srour, Amanda Olson, Stefan O Ciurea, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemiaSyed M Kazmi, Naveen Pemmaraju, Keyur P Patel, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2026
A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaMarina Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.
Leukemia Research|June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidineKunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.
Pageof 44

Showing results (161-170 of 436) with videos related to

Sort By:
Pageof 44
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2025
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class RearrangementsJulie Braish, Hagop Kantarjian, Nicholas J Short, et al.
Leukemia|April 9, 2021
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemiaFrancesco Paolo Tambaro, Harjeet Singh, Emily Jones, et al.
British Journal of Haematology|July 21, 2020
Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemiaShilpa Paul, Nadya Jammal, Neal Akhave, et al.
Blood Advances|September 23, 2021
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapyHussein A Abbas, Zoe Alaniz, Sean Mackay, et al.
Haematologica|July 13, 2019
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantationSamer A Srour, Amanda Olson, Stefan O Ciurea, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemiaSyed M Kazmi, Naveen Pemmaraju, Keyur P Patel, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2026
A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaMarina Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, et al.
Leukemia Research|June 12, 2022
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidineKunhwa Kim, Alexandre Bazinet, Sanam Loghavi, et al.
Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.
Pageof 44